Guangzhou Innogen Pharmaceutical Group Co Ltd (hkse:02591) Share Price

Company Profile

Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHN
https://www.innogenpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
193

Recommended

Why the market may be overpricing future earnings for this lithium producer.

Esther Holloway | 23 June 2026

Mark and Shani run through the business and what our analysts think about the IPO.

Shani Jayamanne | 23 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,012.60	10.70	0.12%
CAC 40	8,385.49	44.78	0.54%
DAX 40	24,740.36	153.22	-0.62%
Dow JONES (US)	51,817.51	150.67	0.29%
FTSE 100	10,461.63	32.78	0.31%
HKSE	23,412.18	75.90	0.33%
NASDAQ	25,431.71	155.33	-0.61%
Nikkei 225	69,174.97	613.41	-0.88%
NZX 50 Index	13,400.66	35.11	-0.26%
S&P 500	7,348.71	16.75	-0.23%
S&P/ASX 200	8,808.40	7.00	0.08%
SSE Composite Index	4,110.81	4.56	0.11%